DBV Technologies (DBVT) Competitors $10.85 -0.15 (-1.36%) Closing price 07/10/2025 03:58 PM EasternExtended Trading$10.85 0.00 (0.00%) As of 07/10/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DBVT vs. CVAC, CALT, GPCR, HROW, PAHC, ABCL, NTLA, AMPH, WVE, and AUPHShould you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Intellia Therapeutics (NTLA), Amphastar Pharmaceuticals (AMPH), WAVE Life Sciences (WVE), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. DBV Technologies vs. Its Competitors CureVac Calliditas Therapeutics AB (publ) Structure Therapeutics Harrow Phibro Animal Health AbCellera Biologics Intellia Therapeutics Amphastar Pharmaceuticals WAVE Life Sciences Aurinia Pharmaceuticals CureVac (NASDAQ:CVAC) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Which has stronger earnings and valuation, CVAC or DBVT? CureVac has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$579.18M2.11$175.50M$0.925.92DBV Technologies$4.15M71.61-$113.92M-$4.92-2.21 Does the media favor CVAC or DBVT? In the previous week, DBV Technologies had 2 more articles in the media than CureVac. MarketBeat recorded 5 mentions for DBV Technologies and 3 mentions for CureVac. CureVac's average media sentiment score of 0.79 beat DBV Technologies' score of 0.47 indicating that CureVac is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CureVac 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in CVAC or DBVT? 17.3% of CureVac shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 1.4% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, CVAC or DBVT? CureVac has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Do analysts recommend CVAC or DBVT? CureVac presently has a consensus target price of $6.83, indicating a potential upside of 25.38%. DBV Technologies has a consensus target price of $14.75, indicating a potential upside of 35.94%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Is CVAC or DBVT more profitable? CureVac has a net margin of 35.44% compared to DBV Technologies' net margin of -3,249.99%. CureVac's return on equity of 30.89% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets CureVac35.44% 30.89% 25.54% DBV Technologies -3,249.99%-278.24%-140.54% SummaryCureVac beats DBV Technologies on 10 of the 17 factors compared between the two stocks. Get DBV Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DBVT vs. The Competition Export to ExcelMetricDBV TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$301.29M$2.96B$5.56B$9.04BDividend YieldN/A2.42%5.25%4.03%P/E Ratio-2.2121.1127.1820.14Price / Sales71.61284.26439.56137.26Price / CashN/A42.7337.5058.41Price / Book7.647.748.085.60Net Income-$113.92M-$54.96M$3.16B$248.43M7 Day Performance-5.97%6.04%3.77%5.15%1 Month Performance24.43%4.47%3.90%7.62%1 Year Performance175.63%6.12%34.22%21.56% DBV Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DBVTDBV Technologies3.6074 of 5 stars$10.85-1.4%$14.75+35.9%+171.6%$301.29M$4.15M-2.2180Gap DownCVACCureVac4.7316 of 5 stars$5.41-0.7%$6.83+26.3%+75.2%$1.22B$579.18M5.88880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.707 of 5 stars$18.73-8.0%$76.17+306.7%-54.8%$1.17BN/A-21.53136HROWHarrow2.635 of 5 stars$31.36-1.2%$61.40+95.8%+36.0%$1.16B$199.61M-56.00180PAHCPhibro Animal Health3.7136 of 5 stars$29.90+6.8%$24.40-18.4%+90.0%$1.13B$1.02B38.331,940Analyst UpgradeHigh Trading VolumeABCLAbCellera Biologics2.5951 of 5 stars$4.03+6.1%$7.50+86.1%+51.8%$1.13B$28.83M-7.20500News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeNTLAIntellia Therapeutics4.6533 of 5 stars$10.25-4.6%$33.37+225.5%-47.5%$1.11B$57.88M-1.96600Gap UpAMPHAmphastar Pharmaceuticals4.3521 of 5 stars$22.86-1.5%$32.33+41.4%-40.6%$1.09B$731.97M8.282,028WVEWAVE Life Sciences4.4452 of 5 stars$7.06+1.6%$20.50+190.4%+42.7%$1.08B$108.30M-8.40240AUPHAurinia Pharmaceuticals2.7839 of 5 stars$7.47-1.6%$11.50+53.9%+62.4%$1.03B$235.13M26.68300 Related Companies and Tools Related Companies CureVac Alternatives Calliditas Therapeutics AB (publ) Alternatives Structure Therapeutics Alternatives Harrow Alternatives Phibro Animal Health Alternatives AbCellera Biologics Alternatives Intellia Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives WAVE Life Sciences Alternatives Aurinia Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DBVT) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DBVT Stock Alerts